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BACKGROUND: The relationship between the percentage of oxygen consumption reserve and percentage of heart rate reserve 
in heart failure patients either on non-optimized or off beta-blocker therapy is known to be unreliable. The aim of this study was to 
evaluate the relationship between the percentage of oxygen consumption reserve and percentage of heart rate reserve in heart failure 
patients receiving optimized and non-optimized beta-blocker treatment during a treadmill cardiopulmonary exercise test. 
METHODS: A total of 27 sedentary heart failure patients (86% male, 50±12 years) on optimized beta-blocker therapy with a left 
ventricle ejection fraction of 33±8% and 35 sedentary non-optimized heart failure patients (75% male, 47±10 years) with a left 
ventricle ejection fraction of 30±10% underwent the treadmill cardiopulmonary exercise test (Naughton protocol). Resting and 
peak effort values of both the percentage of oxygen consumption reserve and percentage of heart rate reserve were, by definition, 
0 and 100, respectively. 
RESULTS: The heart rate slope for the non-optimized group was derived from the points 0.949±0.088 (0 intercept) and 1.055±0.128 
(1 intercept), p<0.0001. The heart rate slope for the optimized group was derived from the points 1.026±0.108 (0 intercept) and 
1.012±0.108 (1 intercept), p=0.47. Regression linear plots for the heart rate slope for each patient in the non-optimized and opti-
mized groups revealed a slope of 0.986 (almost perfect) for the optimized group, but the regression analysis for the non-optimized 
group was 0.030 (far from perfect, which occurs at 1).
CONCLUSION: The relationship between the percentage of oxygen consumption reserve and percentage of heart rate reserve in pa-
tients on optimized beta-blocker therapy was reliable, but this relationship was unreliable in non-optimized heart failure patients.
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INTRODUCTION
Heart failure is considered to be the last stage of heart 
disease, and it is a significant cause of mortality and 
morbidity in the world.1 In recent years, beta-blocker therapy 
has become a primary pharmacologic intervention in patients 
with heart failure. Although improvement in aerobic capacity 
has not been proven,2 the use of this therapy arises from an 
abundance of evidence demonstrating that beta-blockers 
improve survival and reduce hospitalization.3 
The cardiopulmonary exercise test is a well-established 
technique used in heart failure patients to evaluate peak 
oxygen consumption (pVO2). Oxygen consumption (VO2) 
is the best prognostic variable in heart failure patients, and 
it remains so even in the beta-blocker era.4 Aerobic exercise 
training is also a well-established non-pharmacological 
method used to increase pVO2 in heart failure patients. In 
this population, prescription of adequate aerobic exercise 
intensity based on heart rate is crucial to permit both an 
increase in exercise capacity and reasonable control of 
exercise-related risk.1,5,6
Heart rate and VO2 are strongly related from rest to the 
peak of the treadmill cardiopulmonary exercise test in normal 
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individuals.7 This association is especially true when the 
relationship between the percentage heart rate reserve (%HRR) 
and percentage oxygen consumption reserve (%VO2R) is 
considered.8 A previous study demonstrated that the %VO2R 
versus %HRR relationship was unreliable for aerobic effort 
relative intensity assessment in heart failure patients that were 
on or off beta-blocker therapy. However, these patients were 
not optimized with a beta-blocker therapy.8 
The aim of this study was to evaluate the %HRR-
%VO2R relationship in heart failure patients on optimized 
and non-optimized beta-blocker therapy during a treadmill 
cardiopulmonary exercise test.
MATERIALS AND METHODS
Study population
Twenty-seven sedentary heart failure patients (86% male, 
50±12 years) on optimized beta-blocker therapy with a left 
ventricle ejection fraction of 33±8% (echocardiography) and 
thirty-five sedentary non-optimized heart failure patients 
(75% male, 47±10 years) with a left ventricle ejection 
fraction of 30±10% were included in the study. Data were 
collected from March 2006 to February 2008. Characteristics 
of the heart failure patients are listed in Table 1. Patients 
with the following conditions were excluded from the study: 
atrial fibrillation, use of a pacemaker, noncardiovascular 
functional limitations (e.g. osteoarthritis), chronic obstructive 
pulmonary disease, and patients not receiving beta-blocker 
therapy. Optimization was defined as 50 mg/day or more of 
Carvedilol and a resting heart rate between 50 and 60 beats 
per minute for at least three months.9
This protocol was approved by the Ethical Committee of 
the study institution. All patients provided informed consent 
before participation.
Cardiopulmonary exercise test
Heart failure patients receiving optimized or non-optimized 
beta-blocker therapy were asked to refrain from any strenuous 
physical activities for 24 hours before testing and to avoid the 
consumption of any stimulants (e.g., coffee, tobacco, alcohol) 
that especially may influence heart rate. Their last meal was 
ingested at least three hours before the start of the test. All 
subjects underwent the cardiopulmonary exercise test on a 
programmable treadmill (Series 2000; Marquette Electronics; 
Table 1 - Characteristics of the heart failure patients
Characteristics Non-Optimized Optimized p
Etiology:
   Ischemic 40% 37% NS
   Idiopathic dilated cardiomyopathy 57% 48% NS
   Hypertensive 3% 15% <0.0001
NYHA functional class:
   I 20% 42% NS
   II 37% 20% NS
   III 43% 38% NS
Current medications:
Diuretics 94% 93% NS
   Furosemide 74%, 42±15mg/day 63%, 50±30 mg/day NS
   hydrochlorothiazide 20%, 25±0mg/day 30%, 28±9 mg/day NS
ACE inhibitor  82% 80% NS
   enalapril 68%, 25±16mg/day 65%, 38±6 mg/day NS
   Captopril 14%, 25±15mg/day 15%, 94±37 mg/day 0.006
Angiotensin II AT1 receptor antagonists (losartan) 18% 83±29mg/day 20%, 80±27 mg/day NS
b-Adrenergic receptor blocker (Carvedilol) 100%, 21±7mg/day 100%, 53±10 mg/day <0.0001
Spironolactone 70%, 26±4mg/day 35%, 25±0 mg/day NS
Digoxin 64%, 0.25±0mg/day 46%, 0.25±0 mg/day NS
Isosorbide 5-mononitrate 14%, 45±16mg/day 19%, 56±35 mg/day NS
Hydralazine 8%, 37±18mg/day 19%, 80±27 mg/day NS
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Milwaukee, WI, USA) in a temperature-controlled room 
(21-23ºC) between 10:00 a.m. and 3:00 p.m. Patients were 
monitored via standard 12 lead continuous electrocardiograms 
(Max 1; Marquette Electronics; Milwaukee, WI, USA) and 
auscultation for blood pressure. Minute ventilation, oxygen 
uptake, carbon dioxide output, and other cardiopulmonary 
variables were acquired breath-by-breath by a computerized 
system (Vmax 229 model, SensorMedics, Yorba Linda, CA, 
USA). The resting VO2 and heart rate were computed as the 
mean values for the final 30 seconds of the resting period, 
whereas the pVO2 and peak heart rate were the mean values 
for the final 30 seconds of effort before exhaustion. The heart 
rate reserve and oxygen consumption reserve were calculated 
as the difference between the peak and resting heart rate and 
the mean VO2 value, respectively. The %HRR was calculated 
as: %HRR = submaximal heart rate – rest heart rate / heart 
rate reserve x 100. The %VO2R was calculated as: %VO2R 
= submaximalVO2 - restVO2 / VO2reserve x 100.10 Resting 
and peak effort values of both the %VO2R and %HRR were, 
by definition, 0 and 100, respectively. Respiratory exchange 
ratios were recorded as the average of samples obtained during 
each stage for each heart failure patient‘s protocol (modified 
Naughton protocol). A satisfactory cardiopulmonary exercise 
test was characterized by a respiratory exchange ratio of 
greater than 1.05 and symptoms of maximum effort.
Current medication intake
All heart failure patients received a beta-blocker 
(Carvedilol) and an angiotensin converting enzyme inhibitor 
(Enalapril/Captopril) or an angiotensin II AT1 receptor 
antagonist (losartan). The medication profile of the heart 
failure patient group is shown in Table 1. Patients took a 
beta-blocker, Angiotensin Converting Enzyme inhibitors, 
Angiotensin II AT1 receptor antagonists, and Isosorbide 
5-mononitrate two times per day. Half of the daily dose 
was taken in the morning (9:00 a.m.), and the other half 
was taken at night (9:00 p.m.). Diuretics, digoxin, and 
spironolactone were taken in the morning (9:00 a.m.).
STATISTICAL ANALYSIS
Descriptive analyses are presented as mean and standard 
deviation (SD). Linear regression and Pearson product 
moment coefficients were used to determine the relationship 
between the %HRR and %VO2R in both heart failure groups. 
The %HRR was chosen as the independent variable since 
it is currently used in rehabilitation programs to predict 
%VO2R values (i.e., aerobic exercise relative intensity) in 
the absence of a basal cardiopulmonary exercise test. A 
one-sample t-test was used to verify whether the means of 
individual slopes and y-intercepts differed from those of the 
corresponding group regression and from the line of identity 
(i.e., from slope=1 and y-intercept=0). This methodology 
was used in a previous study.10
To compare the rest, peak, and reserve heart rates, age, 
Body Mass Index (Kg/m2), respiratory exchange ratio, 
left ventricle ejection fraction, pVO2, VO2 reserve, and 
current medication
 
between optimized and non-optimized 
beta-blocker therapy groups, we used one-sample t-tests. 
To compare heart failure etiology and New York Heart 
Association functional class, we used Fisher’s exact test.
Data were analyzed using Statistical Package for Social 
Sciences (SPSS) for Windows, v 11.5 (SPSS Inc, Chicago, 
IL). Statistical significance was defined as p < 0.05.
RESULTS
Demographic and clinical characteristics
The non-optimized and optimized groups were well 
matched for age, body mass index and sex (Table 2). The 
only noted difference in etiology was hypertension and in 
current medication intake were Captopril and Carvedilol. 
There were no observed significant differences in the New 
York Heart Association functional class (Table 1).
Ergometric characteristics
As expected, the rest and peak heart rates in the 
optimized beta-blocker therapy group were lower than those 
in the non-optimized group. Heart rate reserve did not differ 
between the groups (Table 2).
The pVO2 and VO2 reserve in the optimized group did 
not differ from those in the non-optimized group. The 
respiratory exchange ratio also did not differ between the 
groups (Table 2).
Regression analysis
The %VO2R was strongly related to the %HRR in 
optimized and non-optimized patients analyzed stage-by-
stage during the cardiopulmonary exercise test (r=0.95, 
p<0.0001 with 9.3 of residual SD and r=0.91, p<0.0001 with 
12.7 of residual SD, respectively). The mean regression line 
coincided with the line of identity in the optimized beta-
blocker therapy group (p=0.31), but this relationship was 
not observed in non-optimized patients (p=0.012) (Figures 
1 and 2).
The mean heart rate slope for the non-optimized group 
was derived from the points 0.949±0.088 (0 intercept) and 
1.055±0.128 (1 intercept) and had a 95% of confidence 
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interval from -0.171 to -0.537 (p<0.0001). The heart rate 
slope for the optimized group was derived from the points 
1.026±0.108 (0 intercept) and 1.012±0.108 and had a 
confidence interval from -0.011 to 0.016 (p=0.47).
Regression linear plots for the heart rate slope during the 
cardiopulmonary exercise test for each patient in the non-
optimized and optimized groups are shown in Figure 3. This 
regression analysis revealed a slope of 0.986 (almost perfect, 
which is achieved with a slope of 1) for the optimized group, 
but the regression analysis for the non-optimized group 
was 0.030 (far from perfect, which occurs at values of less 
than 1).
DISCUSSION
The main finding of this study is that the use of the 
relationship between the %HRR and %VO2R for the aerobic 
effort relative intensity assessment and prescription is 
reliable for heart failure patients on optimized beta-blocker 
therapy but unreliable for non-optimized heart failure 
patients.
Figure 1 - Relationship between percentage of heart rate reserve (%HRR) 
and percentage of oxygen consumption reserve (%VO2R) in optimized 
heart failure patients. The plot represents stage by stage regression of the 
cardiopulmonary exercise test. The dotted is the identity line, the full line 
is regression line
Figure 2 - Relationship between percentage of heart rate reserve (%HRR) and 
percentage of oxygen consumption reserve (%VO2R) in non-optimized heart 
failure patients. The plot represents stage by stage regression of the cardio-
pulmonary exercise test. The dotted line is the identity line, the full line
Figure 3 - Linear regression between 0 intercept and 1 intercept HR slope 
of each optimized(A) and non-optimized(B) heart failure patient
Table 2 - Characteristics of the heart failure patients
Characteristics Non-Optimized Optimized p
Age, years 47±10 50±12 NS
Male, % 86 75 NS
Body Mass Index, Kg/m2 26±4 25±3 NS
Respiratory Exchange Ratio 1.08±0.05 1.10±0.08 NS
LVEF (echocardiography), % 30±10 33±8 NS
pVO2, mLO2.Kg-1.min-1 18±5 19.6±6 NS
VO2 Reserve, mLO2Kg-1.min-1 14,9±4,5 16,6±5,7 NS
Resting Heart Rate, bpm 79±10 58±3 <0.0001
Peak Heart Rate, bpm 125±16 111±19 0.008
Heart Rate reserve, bpm 47±15 53±19 NS
LVEF: Left ventricle ejection fraction; pVO2: Peak Oxygen Consumption.
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Relationship between the %HRR and %VO2R in non-
optimized beta-blocker heart failure patients
The %HRR and %VO2R are strongly related from 
rest to the peak of the treadmill cardiopulmonary exercise 
test in normal individuals.7,8 Motivated by the report of 
this relationship, Mezzani et al investigated the %HRR 
and %VO2R relationship in normal individuals and heart 
failure patients with and without beta-blocker therapy.8 The 
hypothesis that these heart failure patients would have the 
same comportment as normal individuals was frustrated 
by the non-coincidence between the regression line and 
identity line (i.e., the unreliability of the %HRR-%VO2R 
relationship). In this case, the patients on beta-blocker 
therapy were administered a mean Carvedilol dose (22±14 
mg/day) similar to that administered to those in our non-
optimized beta-blocker therapy group (21±7 mg/day). As 
expected, the regression line in our study was similar to 
those reported in other studies for non-optimized heart 
failure patients. Based on the results from Mezzani et al8 
and our study, we cannot assess the aerobic effort relative 
intensity and prescribe exercise using the %HRR in non-
optimized beta-blocker therapy heart failure patients.
Another previous study evaluated the %HRR-%VO2R 
relationship in heart failure patients with and without beta-
blocker therapy and found a perfect identity between these 
variables. However, this study had a number of limitations. For 
example, a fixed rest VO2 value (3.5 mLO2.Kg-1.min-1) was used, 
and no Carvedilol dosage was reported by the authors.11
Relationship between the %HRR and %VO2R in heart 
failure patients on optimized beta-blocker therapy
In our study, we found that the %HRR-%VO2R 
relationship was at the line of identity in optimized heart 
failure patients. This finding provides evidence for the 
reliability of the %HRR-%VO2R relationship, and it shows 
that the %HRR can be used to prescribe exercise training and 
assess aerobic effort relative intensity.
Heart failure syndrome is characterized by an exacerbation 
of the sympathetic system, heart rate increase, and left 
ventricular dysfunction.12 This situation promotes poor cardiac 
function and decreased cardiac output.13,14 The maximal VO2 
depends on cardiac output, which is expressed by the formula: 
VO2 = (systolic volume X heart rate) X arteriovenous oxygen 
difference.15 We hypothesized that optimized heart failure 
patients administered Carvedilol exhibit decreased heart rates 
and improved cardiac function during exercise, probably, more 
than the non-optimized patients. When we evaluated optimized 
patients, however, heart rate and sympathetic control seemed 
to be more rigorous (i.e., attenuated) and cardiac function 
improved during exercise. This may have restored the %HRR-
%VO2R relationship.
Study limitations
Our study is limited by the low number of assessed 
patients. Additionally, we studied only one type of beta-
blocker (Carvedilol) using one method of cardiopulmonary 
exercise test (treadmill).
CONCLUSION
The %HRR-%VO2R relationship in patients on optimized 
beta-blocker therapy was reliable during a treadmill 
cardiopulmonary exercise test, but this relationship was 
unreliable in non-optimized heart failure patients. Further 
studies are needed to fully understand %HRR-%VO2R 
relationship in heart failure patients.
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